CTRI/2017/12/010876进行中(未招募)4 期
Structured Post-marketing surveillance to collect thesafety data of intravitreal aflibercept injection (IVTAFL)in patients of wet age-related maculardegeneration during real world clinical practice. - EYLEA-PMS
Bayer Pharmaceutical Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 进行中(未招募)
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Pms
入排标准
入选标准
- •1 Decision to treat with intravitreal aflibercept
- •injection prior to patient enrolment as per the treating ophthalmologistââ?¬•s routine clinical practice.
- •2 Adult patients with a diagnosis of wet AMD, as
- •an indication approved by the local health authorities
- •(DCGI) for use with intravitreal aflibercept injection.
- •3 Patient or legal delegate signed informed
排除标准
- •1. Participation in a clinical trial of an
- •investigational agent within 30 days
- •2. Patients receiving other anti-VEGF agent in
- •fellow eye.
- •3. Contraindications according to the local
- •prescribing information.
研究者
相似试验
已完成
4 期
A post-marketing study of the marketed product Maxtra® P syrup for the evaluation of safety and effects in children having common cold.CTRI/2021/02/031189Zuventus Healthcare Limited200
已完成
4 期
A post-marketing study of the marketed product Maxtra® P Tablets for the evaluation of safety and effects in children having common cold.CTRI/2021/02/031390Zuventus Healthcare Limited200
招募中
4 期
A post marketing study to evaluate safety and effectiveness of Remogliflozin and Remogliflozin-Metformin Combination in treatment of Diabetes patientsCTRI/2019/11/022062Glenmark Pharmaceuticals Ltd
尚未招募
4 期
Safety and efficacy of Ayukalash on high blood pressure and cholesterol.CTRI/2024/05/067632Med Pharma CRO
已完成
4 期
This is an observational study to determine the efficacy and safety of vitamin-c in facial photodamageCTRI/2010/091/001161Cipla Ltd24
